The SURMOUNT clinical trial program — a landmark series of Phase 3 studies — found that tirzepatide may help adults with obesity lose up to 20–22% of their body weight over approximately 72 weeks, potentially making it one of the most effective pharmacological weight-loss options studied to date. These results have reshaped how clinicians and patients think about medical weight management.
Ready to find out if you qualify? Start Free Assessment — No payment required.
What Is the SURMOUNT Trial Program?
The SURMOUNT trial program is a series of large-scale, randomized, double-blind, placebo-controlled Phase 3 clinical studies sponsored by Eli Lilly and Company to evaluate tirzepatide's efficacy and safety for chronic weight management. The program includes multiple sub-trials — SURMOUNT-1, SURMOUNT-2, SURMOUNT-3, and SURMOUNT-4 — each designed to examine different patient populations and treatment contexts. Together, they represent one of the most comprehensive bodies of evidence assembled for any weight-loss medication.
SURMOUNT-1, the flagship trial, enrolled over 2,500 adults with obesity or overweight who did not have type 2 diabetes. Participants received tirzepatide at doses of 5 mg, 10 mg, or 15 mg once weekly alongside lifestyle intervention, or placebo. The trial ran for 72 weeks and produced headline results that drew significant attention from the endocrinology and obesity medicine communities worldwide.
Key Tirzepatide SURMOUNT Trial Results
In SURMOUNT-1, participants receiving the highest dose of tirzepatide (15 mg) experienced an average body weight reduction of approximately 22.5% compared to just 2.4% in the placebo group — a statistically and clinically significant difference. Nearly 91% of participants on the 15 mg dose achieved at least 5% weight loss, while more than half achieved 20% or greater weight loss. These numbers are particularly notable because they approach outcomes previously seen only with bariatric surgery.
SURMOUNT-2, which focused on adults with type 2 diabetes and obesity, showed similarly compelling results, with participants achieving up to 15.7% average body weight reduction at the highest dose. SURMOUNT-3 evaluated tirzepatide following a period of intensive lifestyle intervention, and SURMOUNT-4 explored the consequences of discontinuing the medication — finding that weight regain was common after stopping, underscoring the chronic nature of obesity as a disease. Understanding how tirzepatide works at the receptor level helps explain why these outcomes are possible.
How Tirzepatide's Dual Mechanism Drives These Outcomes
Tirzepatide is unique among currently available weight-loss medications because it acts as a dual agonist — simultaneously targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual-action mechanism may amplify the metabolic effects seen with GLP-1-only agents like semaglutide, potentially leading to greater reductions in appetite, caloric intake, and body fat. To explore the clinical differences in detail, visit our semaglutide vs. tirzepatide comparison page.
Beyond weight loss, SURMOUNT participants also experienced meaningful improvements in secondary metabolic markers, including reductions in waist circumference, blood pressure, fasting insulin levels, and triglycerides. These cardiometabolic benefits suggest that tirzepatide's effects may extend well beyond aesthetics — potentially supporting long-term metabolic health for eligible patients. As with any medication, individual results vary and outcomes depend on adherence, lifestyle factors, and clinical suitability.
Safety Profile Observed in the SURMOUNT Trials
The most commonly reported adverse events in the SURMOUNT trials were gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation. These effects were generally mild to moderate in severity and most often occurred during the dose-escalation phase of treatment. The majority of participants who experienced gastrointestinal side effects reported improvement over time as the body adjusted to the medication.
Serious adverse events were infrequent and comparable in rate between the tirzepatide and placebo groups in most analyses. Discontinuation due to adverse events was reported in approximately 4–7% of participants across dose groups. As with any prescription medication, a thorough clinical evaluation is essential before starting tirzepatide — which is why every EdenRx patient is reviewed by a licensed provider before any treatment plan is initiated. If you are in New York and want region-specific guidance, visit our tirzepatide New York page for more information.
What SURMOUNT-4 Tells Us About Long-Term Treatment
One of the most clinically instructive findings from the SURMOUNT program came from SURMOUNT-4, which examined what happens when tirzepatide is discontinued after an initial period of treatment. Participants who stopped taking tirzepatide regained approximately two-thirds of their prior weight loss within one year, while those who continued the medication maintained their weight reduction. This finding reinforces the scientific consensus that obesity is a chronic, relapsing condition requiring long-term management — not a short-term fix.
For patients and providers alike, these results highlight the importance of sustainable, ongoing treatment strategies rather than viewing weight-loss medication as a temporary intervention. EdenRx's structured programs are designed with this long-term perspective in mind, offering tiered support that evolves as patients progress. To understand what ongoing treatment may cost, review our transparent pricing information with no hidden fees.
Thinking about starting? Your journey begins with one step. Take the Free Assessment to see if tirzepatide may be right for you — no payment required to get started.
Why Provider Review Matters
Clinical trial results represent population-level averages, and individual responses to tirzepatide can vary considerably depending on factors such as baseline weight, metabolic health, medication history, and lifestyle. This is precisely why EdenRx requires every patient to complete a comprehensive intake assessment before any prescription is considered — not to create barriers, but to ensure that each treatment plan is clinically appropriate and individually tailored.
Our platform connects patients in Florida and New York with licensed providers who review each case with the same rigor applied in clinical settings. This provider-first model means you're not receiving a one-size-fits-all protocol — you're receiving a care plan informed by real clinical evidence, including data from trials like SURMOUNT. Access to cutting-edge pharmacotherapy should be paired with equally rigorous medical oversight, and that is the standard EdenRx is committed to upholding.
Built from Eden Med Spa — real patients, real treatments.
Frequently Asked Questions
Q: What were the most significant tirzepatide SURMOUNT trial results? A: In SURMOUNT-1, participants on the 15 mg dose of tirzepatide experienced an average weight reduction of approximately 22.5% over 72 weeks, compared to 2.4% in the placebo group. Results varied across dose levels and individual participants.
Q: Is tirzepatide FDA-approved for weight loss based on the SURMOUNT data? A: Yes. Tirzepatide received FDA approval for chronic weight management under the brand name Zepbound in November 2023, based in part on the SURMOUNT clinical trial data. Eligibility depends on individual clinical factors.
Q: How does tirzepatide compare to semaglutide for weight loss? A: Head-to-head trial data suggest tirzepatide may produce greater average weight loss than semaglutide, potentially due to its dual GIP/GLP-1 receptor activity. Visit our semaglutide vs. tirzepatide page for a full clinical comparison.
Q: Will I regain weight if I stop taking tirzepatide? A: SURMOUNT-4 data indicate that discontinuing tirzepatide may lead to significant weight regain, with participants recovering approximately two-thirds of lost weight within a year. This underscores the importance of a long-term treatment approach.
Q: What side effects were reported in the SURMOUNT trials? A: The most common side effects were gastrointestinal, including nausea, diarrhea, and vomiting. These were generally mild to moderate and most frequent during dose escalation. Individual experiences vary, and a provider review is essential before starting.
Q: How do I find out if I qualify for tirzepatide through EdenRx? A: You can start a free assessment at any time. EdenRx serves patients in Florida and New York, and all responses are reviewed by a licensed provider to determine if tirzepatide may be clinically appropriate for you.
The Bottom Line
The tirzepatide SURMOUNT trial results represent a meaningful advance in the clinical science of obesity medicine, offering evidence that significant, sustained weight loss may be achievable for eligible individuals through a once-weekly injectable medication. The data are compelling — but they are also a starting point, not a guarantee. Weight loss outcomes vary by individual, and responsible use of tirzepatide requires proper medical evaluation, ongoing monitoring, and a commitment to long-term health.
EdenRx is here to help patients in Florida and New York access provider-reviewed tirzepatide treatment through a transparent, science-backed telehealth platform. If the SURMOUNT data has you wondering whether tirzepatide could be part of your weight management plan, the next step is simple.
Take the first step today. Start Your Free Assessment — reviewed by a licensed provider, no payment required to begin.
